Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 16/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994742 | 1.00 | NR1H2 (0.56) | NR1H2NR1H3MAPTL3MBTL1SCN9A | |
| SCHEMBL994412 | 0.99 | NR1H2 (0.56) | NR1H2NR1H3MAPTL3MBTL1SCN9A | |
| SCHEMBL994793 | 0.97 | NR1H2 (0.52) | NR1H2NR1H3MAPT | |
| SCHEMBL995055 | 0.97 | NR1H2 (0.52) | NR1H2NR1H3MAPT | |
| SCHEMBL994778 | 0.96 | NR1H2 (0.52) | NR1H2NR1H3MAPT | |
| SCHEMBL997425 | 0.92 | NR1H2 (0.60) | NR1H2NR1H3MAPTL3MBTL1 | |
| SCHEMBL995440 | 0.92 | NR1H2 (0.60) | NR1H2NR1H3MAPTL3MBTL1 | |
| SCHEMBL12392089 | 0.92 | NR1H2 (0.53) | NR1H2NR1H3MAPTSCN9A | |
| SCHEMBL12392143 | 0.92 | NR1H2 (0.53) | NR1H2NR1H3MAPTSCN9A | |
| SCHEMBL995268 | 0.91 | NR1H2 (0.60) | NR1H2NR1H3MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008306-B2 | Quinoline compounds | KOWA COMPANY, LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2272843-A1 | QUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| EP-2272843-A1 | QUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100016327-A1 | QUINOLINE COMPOUNDS | KOWA COMPANY, LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016327-A1 | QUINOLINE COMPOUNDS | NR1H2, NR1H3, LDLR | NR1H2 1/4885NR1H3 2/4885MAPT 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.